Skip to content

Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment

Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00351676
Enrollment
452
Registered
2006-07-13
Start date
2006-02-28
Completion date
2007-07-31
Last updated
2007-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Heart Failure, Congestive, Pneumonia, Pulmonary Disease, Chronic Obstructive

Keywords

Drug Therapy, Hospitals, Teaching, Hospitals, Community, Interprofessional relations, Patient Care Team, Pharmacists, Pharmacy Service, Hospital, Comparative Study, Hospitalization

Brief summary

We, the researchers, propose to link a clinical pharmacist with an internal medicine or family medicine team to provide pharmaceutical care to all patients assigned to the team. The hypothesis is that through this team based approach, pharmacists will act as a resource for providing pharmacotherapeutic advice during the drug therapy decision making process and promote optimal drug use by identifying and resolving actual and potential drug related problems. This study is designed to test this hypothesis, by assessing the impact of this intervention on evidence based, quality of drug therapy indicators, for patients admitted with heart failure (HF), chronic obstructive pulmonary disease (COPD), community acquired pneumonia (CAP), type 2 diabetes mellitus (T2DM), and stable coronary artery disease (CAD).

Detailed description

The overall goal of the COLLABORATE study is to improve processes of care and patient outcomes by optimizing drug therapy via a hospital pharmacy practice model that integrates clinical pharmacists into the patient care team. The intervention consists of a clinical pharmacist assigned to the patient care team for the purpose of providing proactive clinical pharmacy services. The study pharmacist will be available during normal office hours 5 days per week to provide clarification of the patient's medication history, identify and resolve actual and potential patient specific drug related problems/issues, participate in patient care rounds, provide drug information to the patient care team, provide patient education and discharge medication counselling, and provide physician and/or nursing staff education. The anticipated pharmacist to patient ratio is approximately 1:20. Control patients will receive usual care. Usual care consists of reactive clinical pharmacy services (i.e. drug related issues identified as orders are received, or by patient profile review) provided by a ward based, not team based, clinical pharmacist.

Interventions

BEHAVIORALIntegration of a team based clinical pharmacist

Sponsors

Capital Health, Canada
CollaboratorOTHER
University of Alberta
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Consecutive patients \> 18 years of age admitted to participating internal and family medicine teams during the 1 year study period will be eligible to receive the pharmacist intervention. For the purposes of data analysis, patients with a most responsible or primary diagnosis of HF, COPD, CAP, T2DM, and CAD will be included.

Exclusion criteria

* Residence outside the Capital Health catchment * Admitted for ≤ 2 days * Palliative care * Transferred to another team

Design outcomes

Primary

MeasureTime frame
Improvement in proportion of quality indicators achieved, for target diseases as a most responsible or primary diagnosis, between groups.in hospital

Secondary

MeasureTime frame
Differences in condition-specific achievement of drug therapy quality indicators;in hospital
Differences in 6 month hospital readmission rate;6 months
Differences in number, type, acceptance rate, and expected impact of all pharmacist interventions;in hospital
Qualitative evaluation of the impact of the intervention via interviews with the participating pharmacists and physicians.in hospital

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026